Introduction and History of Botulinum Toxin
By: Pharma Tips |
Views: 3336 |
Date: 19-Jun-2011
Botulinum toxin (abbreviated either as BTX or BoNT) is produced by Clostridium botulinum, a gram-positive anaerobic bacterium. The clinical syndrome of botulism can occur following ingestion of contaminated food, from colonization of the infant gastrointestinal tract, or from a wound infection.
INTRODUCTION
Botulinum toxin (abbreviated either as BTX or BoNT) is produced by Clostridium botulinum, a gram-positive anaerobic bacterium. The clinical syndrome of botulism can occur following ingestion of contaminated food, from colonization of the infant gastrointestinal tract, or from a wound infection.
BoNT is broken into 7 neurotoxins (labeled as types A, B, C [C1, C2], D, E, F, and G), which are antigenically and serologically distinct but structurally similar. Human botulism is caused mainly by types A, B, E, and (rarely) F. Types C and D cause toxicity only in animals.
The BoNT molecule is synthesized as a single chain (150 kD) and then cleaved to form the dichain molecule with a disulfide bridge. The light chain (~50 kD - amino acids 1-448) acts as a zinc (Zn2+) endopeptidase similar to tetanus toxin with proteolytic activity located at the N-terminal end.
The heavy chain (~100 kD - amino acids 449-1280) provides cholinergic specificity and is responsible for binding the toxin to presynaptic receptors; it also promotes light-chain translocation across the endosomal membrane.
HISTORY:-
The German physician and poet Justinus Kerner (1786-1862) first developed the idea of a possible therapeutic use of botulinum toxin, which he called "sausage poison."
-In 1870, Muller (another German physician) coined the name botulism. The Latin form is botulus, which means sausage.
-In 1895, Professor Emile Van Ermengem, of Belgium, first isolated the bacterium Clostridium botulinum.
-In 1928, Dr. Herman Sommer, at the University of California, San Francisco, first isolated in purified form botulinum toxin type A (BoNT-A)
as a stable acid precipitate.
-In 1946, Dr. Edward J Schantz succeeded in purifying BoNT-A in crystalline form–cultured Clostridium botulinum and isolated the toxin.
-In 1949, Dr. Burgen's ASV group discovered that botulinum toxin blocks neuromuscular transmission.
-In the 1950s, Dr. Vernon Brooks discovered that when BoNT-A is injected into a hyperactive muscle, it blocks the release of acetylcholine ] from motor nerve endings.
-In 1973, Dr. Alan B. Scott, of Smith-Kettlewell Eye Research Institute, used BoNT-A in monkey experiments; in 1980, he used BoNT-A for
the first time in humans to treat strabismus.
-In December 1989, BoNT-A (BOTOX®) was approved by the US Food and Drug Administration (FDA) for the treatment of strabismus,
blepharospasm, and hemifacial spasm in patients aged younger than 12 years.
-On December 21, 2000, BoNT-A received FDA approval for treatment of cervical dystonia.
-In 2001, the United Kingdom approved BOTOX®, synthesized by Allergan, for axillary hyperhidrosis (excessive sweating). Canada approved
BOTOX® for axillary hyperhidrosis, focal muscle spasticity, and cosmetic treatment of wrinkles at the brow line.
-On April 15, 2002, the FDA announced the approval of BOTOX® Cosmetic to temporarily improve the appearance of moderate-to-severe
frown lines between the eyebrows (glabellar lines).
-In July 2004, the FDA approved BOTOX® to treat severe underarm sweating, known as primary axillary hyperhidrosis, that cannot be
managed by topical agents, such as prescription antiperspirants.
-Although it has not been approved by the FDA for any other indications, the acceptance of BoNT-A use for the treatment of spasticity and
muscle pain disorders is growing, with approvals pending in many European countries.
-The clinical use of BoNT-B has been studied, and several products currently are available commercially (eg, MyoBloc, in the United States;
NeuroBloc, in Europe). MyoBloc was approved by the FDA on December 8, 2000, for treatment of cervical dystonia, to reduce the severity
of abnormal head position and neck pain.
People Searching On This Page:
-
history of botulinm toxin
-
mechnsim of botox
-
the light chain (~50 kd - amino acids 1-448) acts as a zinc (zn2 ) endopeptidase similar to tetanus toxin with proteolytic activity located at the n-terminal end. the heavy chain (~100 kd - amino acids 449-1280) provides cholinergic specificity and is res
-
pharmacognosy toxins
-
kettlewell.com loc:IN
-
pharmacognosy introduction about plant toxins
-
1950 dr brooks botulinum
-
introduction and development of toxins
-
december 1989, botox® approved by us fda for strabismus, blepharospasm, and hemifacial spasm in patients younger than 12 years.
-
historical development of pharmacognosy
-
Introductiom of history in pharmocognosy
-
introduction of indian history pharmacognosy
-
introduction and history of toxin
-
history pharmacognosy
-
email kettlewell.com loc:IN